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Blochemotherapy
Study shows increased
TI-E LNIVERSffi'OFT™5 response rates and
MDAN)ERSON fosters hope for
O\NCERCENIER patients with
Making Cancer Historf advanced melanoma.
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Melanoma Protocols
Clinical trials focus
on primary and
adjuvant treatme nt
of regional and
advanced melanoma.

The ABCs
Valuable Lesson
House Call offers
tips on how to
identify the early
Warning signs of
melanoma.
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Difficult Choices
Options exist for
screening and
prevention of breast
cancer in women
at increased risk.

NID Anderson

Early Detection of
Melanoma Spread May
Increase Survival Benefits
of Adjuvant Therapy

Professor of Surgi,cal Oncolo!fY Merrick Ross, M.D., (right) and Senior Research Nurse
· Allogeneic vaccines,
autologous vaccines, and biochemotherapy are among the agents being examined as
adjuvant therapy for patients s1tch as
with m�lan01na.

Marcia Emerson, RN., examine patient
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by Kerry L. Wright

anrzr of the skin is
the most common
form of cancer, and
although only 4 %
of skin cancers are melanoma,
the disease accounts for nearly
80 % of skin cancer deaths7, 700 this year alone, accord
ing to the American Cancer
Society.

If detected early, melanoma is
highly curable, but the presence of
lym phatic disease has long been
known to indicate a much poorer
prognosis. Improvements in sentinel
node mapping over the last few years,
however, are allowing earlier detec
tion and prediction of the spread of
melanoma and improving patients'
chances to benefit from an increas
ing number of available adjuvant
therapy protocols.
''The presence or absence of
spread of melanoma to the sentinel
lymph node is the single most impor
tant predictor of outcome for the
patient," said Jeffrey Lee, M.D., an
associate professor in the Department
of Surgical Oncology and medical
director of the Melanoma and Skin
Center at The University of Texas
M. D. Anderson Cancer Center.
Sentinel node mapping was first
(Continued on next page)

Medical Oncologist
Omar Eton, M.D.,
Oncology Nurse
Specialist Cynthia
Hodges, M.S.N.,
and Professor Agop
Bedikian, M.D., (wjt
to 1ight) from the
Depa:rtment of
A1elanoma/Sarcoma
Medical Oncol.ogy
meet with
to
discuss hi-s treatment.

include dacarbazine with a bcl-2
antisense oligonucleotide and
paclitaxel in combination with a
matrix metalloproteasc inhibitor.
Biochemotherapy's impact on
patients with stage TV melanoma
has recently been demonstrated
in a large, randomized phase III
clinical trial comparing sequential
biochemotherapy to standard
chemotherapy. Results of the
M. D. Anderson trial, which accrued
190 patients over five years, were
presented at the American Society
of Clinical Oncology meeting in
New Orleans in May by principal
investigator Omar Eton, M.D., a
medical oncologist in the Depart
ment of Melanoma/Sarcoma Medical
Oncology. "In this randomized trial
of patients with poor prognostic
variables, the response rate for
sequential biochemotl1erapy was
48%, which was almost twice that for
chemotherapy alone," said Dr. Eton.
Although the complete response rate
for biochemotherapy was less than
15%, it was three times higher than
the complete response rate for
chemotherapy alone. Biochemo
therapy also resulted in modest but
significant improvement in time to
progression and overall survival
rate when compared to standard
chemotherapy. Dr. Eton is now

pursuing a dose intensification trial
of biochemotherapy in an effort to
augment complete response rates
and control side effects.
"The one direction we are going
now is to enhance the overall effi
ciency ofbiochemotherapy, specifi
cally aimed at higher complete
remission rates,» said Agop Bedikian,
M.D., a professor in the Department
of Melanoma/Sarcoma Medical
Oncology. Dr. Bedikian is investigat
ing tile efficacy of second-generation
taxanes such as BMS -l84476, which
will be examined in a phase II
clfoical trial beginning in August.
He plans to deter mine whether
new taxanes will be even more
powerful and less toxic than existing

ones, and he hopes that they wjll
eventually be used to create new
biochemotherapy programs.
As physicians prescribe and
develop treatments, Hodges stays
beside the patients, managing thei1·
symptoms and offering encourage
ment. She knows, as do most of
tl1em, that advanced-stage melanoma
is often a deadly disease, but she also
knows that biochemotherapy may be
their best option.
"All the patients have such a
desire to live and to b e there for their
families in the future," Hodges said.
"Even when patients know they have
a terminal illness and they could die
any time, it is always tomorrow, never
today, for most patients."•

trial with a similar protocol compar
ing interferon and biochemotherapy.
While trials evaluate the effective
ness of biochemotherapy. a vaccine
approach to adjuvant therapy is also
being investigated at M. D. Anderson.
A multicenter, randomized phase III
o·ial sponsored by the John Wayne
Cancer Institute is comparing an
allogeneic, whole-cell vaccine called
CancerVa.x with BCG, a nonspecific
immune stimulator that is also a
component of the vaccine.
The vaccine is prepared from
tumor cells that are grown in culture,
killed with radiation therapy, and
mixed with BCG before being
injected into patients. Because it is
made from whole cells, the vaccine
contains a variety of antigens that
should be similar to antigens on a
patient's own melanoma cells.
"In theory, when the body sees

those same antigens on its own
melanoma cells, it may be encour
aged to view them as being foreign
and kill them," said Dr. Ross, who
is the principal investigator of the
M. D. Anderson portion of the
allogeneic vaccine trial.
Autologous n,mor-derived
vaccines are also being investigated
as adjuvant therapy for stage III and
stage IV disease in a phase I study
led by Omar Eton, M.D., a medical
oncologist in the Department of
Melanoma/Sarcoma Medical
Oncology.
Each autologous vaccine is made
by surgically removing a patient's
tumor and extracting from the tumor
cells heat shock protein gp96, an
evolutionarily conser ved glycoprotein
that binds and shuttles peptides to
important immune-signaling mol
ecules. The investigators exploit

this molecular chaperone by using
it to extract the patient's own tumor
specific peptides and then as a non
specific immune primer for profes
sional antigen-presenting cells. When
the peptides are displayed on the
surface of a patient's antigen-present
ing cells, a specific T-cell immune
response can be generated against
the tumor without having to identify
individual peptides or select patients
based on immunological phenotypes.
Researchers hope to show that using
gp96 and other chaperones together
with peptides is more effective than
using peptides alone.
"Patients enrolled in the adjuvant
setting had advanced melanoma with
disease that was resected as part of
their routine management. Several
of these patients have remained alive
with no other treatment for more
(Continued on page 4)
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No Easy Answers:

Women at Increased Risk for
Breast Cancer Face Difficult Choices

T

by Stephanie Deming

he spring of 1998
brought good news
for women at in
creased risk for
breast cancer: dramatic
results from the Breast Cancer
Prevention Trial showed that
tamoxifen significantly lowered
the risk of breast cancer in
f
women at increased risk o the
disease. The National Cancer
Institute announced that
tamoxifen was now an option
for women at increased -risk,
and a flurry of articles in the
medical and lay press spoke of
''preventing cancer with a pill. "
Despite the good news about
tamoxilen, however, women at
increased risk for breast cancer
still face difficult decisions because
several prevention options are
available, and all have both benefits
and drawbacks.
According to Therese Bevers,
M.D., an assistant professor in the
Department of Clinical Cancer
Prevention and medical director of
the Cancer Prevention Center at The
University of Texas M. D. Anderson
Cancer Center, the first step for a
woman concerned about her risk of
breast cancer is to quantify that risk.
For women who most likely do
not have a genetic predisposition for
breast cancer, risk is estimated using
a validated risk-assessment tool called
the Gail model. The model, which
has been refined several times since
it was originally published in the
mid- l 980s, currently takes into
account seven factors: age, age at
menarche, age at first birth, number
6 / MD Anderson OneoLog

of first-degree relatives with breast
cancer, number of breast biopsies,
number of biopsies showing hyper
plasia, and race. The calculations
required to arrive at a risk estimate
are complicated, but the ational
Cancer Institute recently made
available a computerized version of
the Gail model that greatly simplifies
the process. The health-care provider
simply inputs data on the seven
parameters, and the software pro
duces a detailed one-page printout
describing the woman's five-year
and lifetime risks of breast cancer.
A five-year risk higher than l. 7%
is considered to be increased.
"Having something quantitative is
very nice," Dr. Bevers said. "You can
actually sit down in the office with
your patient and-recognizing the
limitations of the model [for in
stance, it does not take into account

cancer in second-degree relatives or
age at diagnosis in first-degree
relatives)-say, 'this is an estimate,
and we can go from here.'"
For women in whom evidence of
a genetic predi position is strong, the
Cancer Prevention Center's initial
approach is different. These women
complete an extensive family history
questionnaire before their first clinic
visit, and specialists in the cenler use
this information lo calculate the ri k
of a genetic mutation. When the
woman comes in for her risk counsel
ing session, said Dr. Bevers, her
probability for having a genetic
mutation is carefully explained to
her, as are the ramifications of testing
positive for a mutation, which in
clude employment and insurance
issues. According to Dr. Bevers,
women who are concerned about a
genetic predisposition hould receive

The Cancer Prevention Center counsels women about thei.r breast cancer prevention
options. Here, Dr. Therese Bevers, an assistant projessw in the Department of Clinical
Cancer Prevention, ta/.ks to

